Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
2013 · The Lancet Oncology · 384 citations
https://doi.org/10.1016/s1470-2045(13)70411-x
H
Hanna Bandos
NRG Oncology(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
105
Papers
3.9K
Citations
23
h-index
41
i10-index
Hanna Bandos is an academic researcher from NRG Oncology. The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & Estrogen and related hormone effects. The author has an h-index of 23, co-authored 90 publications.
ORCID: 0000-0003-1798-8054Papers by this author
worksLong-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30
2017 · JNCI Journal of the National Cancer Institute · 124 citations
https://doi.org/10.1093/jnci/djx162
Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
2013 · JNCI Journal of the National Cancer Institute · 113 citations
https://doi.org/10.1093/jnci/djt321
Association of Polymorphisms in <i>FCGR2A</i> and <i>FCGR3A</i> With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer
2016 · JAMA Oncology · 111 citations
https://doi.org/10.1001/jamaoncol.2016.4884
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
2020 · Clinical Cancer Research · 61 citations
https://doi.org/10.1158/1078-0432.ccr-20-0152
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
2019 · JNCI Journal of the National Cancer Institute · 55 citations
https://doi.org/10.1093/jnci/djz032
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat